A Delphi consensus study with 89 experts from 17 countries identified 30 extra-pharmacological variables that are important or very important for reporting the setting in psychedelic clinical trials. These variables, forming the ReSPCT guidelines, cover physical environment, dosing session procedure, therapeutic framework and protocol, and subjective experiences. The findings reveal significant ambiguities in current conceptualizations of set and setting. The guidelines provide a new standard for designing and documenting contextual factors in psychedelic research.
A pilot program offered group-based therapy with three ketamine sessions at a psychedelic dose to eight Indigenous participants and two Elders, in partnership between Roots to Thrive and the Snuneymuxw First Nation. Thematic analysis of interviews and feedback revealed that participants experienced significant benefits, including the importance of Indigenous team members, traditional healing approaches, and authentic relationships. Challenges were also noted. The work highlights the need to address colonial legacies and integrate Indigenous Ways of Knowing for culturally safe psychedelic therapies.